Olmesartán/Hidroclorotiazida Tarbis (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan blocks the AT1 receptors for angiotensin II, preventing vasoconstriction and aldosterone‑mediated sodium retention. This leads to relaxed blood vessels and reduced blood volume. When paired with hydrochlorothiazide, which increases urinary excretion of sodium and water, the overall effect is a more pronounced and sustained reduction in blood pressure.

The exact dose is determined by the prescribing clinician based on the patient’s blood‑pressure readings, renal function, and other medical conditions. Physicians typically start with a low‑strength tablet and may adjust the dose or strength according to therapeutic response and tolerability.

The combination is contraindicated in pregnancy because olmesartan can cause fetal toxicity and birth defects. It is also not recommended for breastfeeding mothers, as the drugs may pass into breast milk and affect the infant. Alternative antihypertensives should be considered for these populations.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Olmesartan/hydrochlorothiazide offers a dual mechanism—blocking the renin‑angiotensin system and promoting diuresis—in a single tablet, which can improve adherence compared with taking two separate drugs. Compared with ACE inhibitors, ARBs have a lower incidence of cough, and the added thiazide component often yields greater blood‑pressure reduction than monotherapy.

Store the tablets at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

The medication is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a full glass of water and avoid crushing or chewing it, unless otherwise directed by a healthcare professional.

Serious adverse events include severe hypotension, acute kidney injury, hyperkalemia, angioedema, and rare but life‑threatening allergic reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden loss of kidney function, or unexplained severe dizziness.

The combination should be avoided in patients with known hypersensitivity to olmesartan, hydrochlorothiazide, or any component of the formulation. It is also contraindicated in pregnancy, in individuals with severe renal impairment, and in those with electrolyte disturbances such as hyperkalemia or severe hyponatremia.